These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 23387769)

  • 1. Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease.
    Willegaignon J; Sapienza MT; Coura Filho GB; Traino AC; Buchpiguel CA
    Med Phys; 2013 Feb; 40(2):022502. PubMed ID: 23387769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follow-up on thyroidal uptake after radioiodine therapy: how robust is the peri-therapeutic dosimetry?
    Eschner W; Kobe C; Schicha H
    Z Med Phys; 2011 Dec; 21(4):258-65. PubMed ID: 21719262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients.
    Canzi C; Zito F; Voltini F; Reschini E; Gerundini P
    Med Phys; 2006 Aug; 33(8):2860-7. PubMed ID: 16964862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A thermoluminescent method for the evaluation of the
    Meftah S; Kraiem T
    Radiat Environ Biophys; 2021 May; 60(2):289-298. PubMed ID: 33797646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning.
    Willegaignon J; Sapienza MT; Coura-Filho GB; Watanabe T; Traino AC; Buchpiguel CA
    Med Phys; 2014 Jan; 41(1):012503. PubMed ID: 24387527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dosimetric approach to patient-specific radioiodine treatment of Graves' disease with incorporation of treatment-induced changes in thyroid mass.
    Traino AC; Di Martino F; Lazzeri M
    Med Phys; 2004 Jul; 31(7):2121-7. PubMed ID: 15305466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possibility of limiting the un-justified irradiation in (131)I therapy of Graves' disease: a thyroid mass-reduction based method for the optimum activity calculation.
    Traino AC; Grosso M; Mariani G
    Phys Med; 2010 Apr; 26(2):71-9. PubMed ID: 19800827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.
    Traino AC; Xhafa B
    Med Phys; 2009 Apr; 36(4):1212-8. PubMed ID: 19472628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iodine-131 treatment of hyperthyroidism: significance of effective half-life measurements.
    Berg GE; Michanek AM; Holmberg EC; Fink M
    J Nucl Med; 1996 Feb; 37(2):228-32. PubMed ID: 8667049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Optimized radioiodine therapy for Graves' disease: two MIRD-based models for the computation of patient-specific therapeutic 131I activity.
    Carlier T; Salaun PY; Cavarec MB; Valette F; Turzo A; Bardiès M; Bizais Y; Couturier O
    Nucl Med Commun; 2006 Jul; 27(7):559-66. PubMed ID: 16794516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The radioiodine turnover rate as a determinant of radioiodine treatment outcome in Graves' disease.
    van Isselt JW; Broekhuizen-de Gast HS
    Hell J Nucl Med; 2010; 13(1):2-5. PubMed ID: 20411161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalization of radioiodine treatment for Graves' disease: a prospective, randomized study with a novel method for calculating the optimal 131I-iodide activity based on target reduction of thyroid mass.
    Orsini F; Traino AC; Grosso M; Guidoccio F; Boni G; Volterrani D; Mariani G
    Q J Nucl Med Mol Imaging; 2012 Dec; 56(6):496-502. PubMed ID: 23358401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?
    Kobe C; Eschner W; Wild M; Rahlff I; Sudbrock F; Schmidt M; Dietlein M; Schicha H
    Nucl Med Commun; 2010 Mar; 31(3):201-5. PubMed ID: 19907353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Estimation of effective half life of 131I in radioiodine therapy for Graves' disease using a single radioiodine uptake measurement].
    Watanabe M; Ito K; Mimura T; Ishikawa N; Ino E; Saitoh T; Tsuji H; Tsuchiya T
    Kaku Igaku; 1993 Sep; 30(9):1055-62. PubMed ID: 8230826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [F-qi-FDG PET of the thyroid gland in Graves' disease].
    Börner AR; Voth E; Wienhard K; Wagner R; Schicha H
    Nuklearmedizin; 1998; 37(7):227-33. PubMed ID: 9830612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning.
    Willegaignon J; Sapienza MT; Buchpiguel CA
    Clin Nucl Med; 2013 Apr; 38(4):231-6. PubMed ID: 23429386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calculation of therapeutic activity of radioiodine in Graves' disease by means of Marinelli's formula, using technetium (
    Szumowski P; Mojsak M; Abdelrazek S; Sykała M; Amelian-Fiłonowicz A; Jurgilewicz D; Myśliwiec J
    Endocrine; 2016 Dec; 54(3):751-756. PubMed ID: 27553050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretherapeutic dosimetry before 131I therapy of benign thyroid disease. A clinical practice assessment of dosimetric parameters.
    Krohn T; Behrendt FF; Heinzel A; Müller B; Mottaghy FM; Verburg FA
    Nuklearmedizin; 2015; 54(3):131-6. PubMed ID: 25487217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I.
    Traino AC; Di Martino F; Grosso M; Monzani F; Dardano A; Caraccio N; Mariani G; Lazzeri M
    Phys Med Biol; 2005 May; 50(9):2181-91. PubMed ID: 15843745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.